Columbus Venture Partners
- Company typePrivate
- Founded2016
- HeadquartersMadrid, Spain
- Headcount11–50
- GTM typeB2B
- OfferingServices
Columbus Venture Partners firmographics
Firmographics- Name
- Columbus Venture Partners
- Legal name
- COLUMBUS VENTURE PARTNERS, S.G.E.I.C., S.A.U.
- Website
- https://columbusvp.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Columbus Venture Partners industry classification
Industry- Product category
- Life Sciences Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
Keywords
Where Columbus Venture Partners is headquartered
LocationHeadquarters
- HQ city
- Madrid
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Columbus Venture Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others
Revenue model
- Fund Management Fees: Columbus generates revenue through management fees charged on funds under management, typically a percentage of committed capital during the investment period and a reduced rate thereafter.
- Carried Interest: The firm earns carried interest (carry) from successful exits of portfolio companies, aligning investor and manager interests and providing upside participation in returns above the hurdle rate.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Columbus Venture Partners product offering
Product offeringCore offering
Columbus Venture Partners is an independent venture capital fund manager that invests in early- and growth-stage therapeutic and industrial biotechnology companies, primarily in Spain and Europe, through a series of dedicated life science funds. Across five funds (I–V) totaling €400M+ in committed capital, the firm originates companies internally, builds biotech infrastructure, and delivers exits such as Viralgen (acquired by Bayer for €4B) and Sanifit (acquired by Vifor Pharma for €205M+). The firm also develops the Biocity by Columbus biotech park and operates Fundación Columbus for rare pediatric gene therapies.
Product overview
Columbus Venture Partners is a venture capital fund manager specializing in life science investments, founded in 2016 by Javier García Cogorro and Damià Tormo. The company operates as a multi-fund platform managing five life science investment funds with €400 million under management combined, split 50% in therapies and 50% in industrial development. The fund family includes Columbus Innvierte Life Science Fund I (€42M), Columbus Life Science Fund II (€74M), Columbus Life Sciences Fund III (€120M), Columbus Life Sciences Fund IV (€150M), and Columbus Innvierte Life Sciences Fund V (€210M target). The investment strategy combines deep therapeutic insight with industrial vision, not only investing in companies but also originating biotech solutions and building bioindustries. Additional offerings include the Biocity by Columbus biotech real estate initiative in the Basque Country and Fundación Columbus for charitable gene therapy programs for rare childhood diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Columbus Innvierte Life Science Fund I First dedicated life science venture fund with €42M in committed capital, focused on early-stage biotech investments and company origination for institutional LPs.
- Columbus Life Science Fund II Second life science venture fund with €74M in committed capital, continuing the strategy of investing in therapeutic and industrial biotech companies with differentiated science.
- Columbus Life Sciences Fund III Third life science venture fund with €120M in committed capital, scaling Columbus's presence in the Spanish and European biotech venture capital ecosystem.
- Columbus Life Sciences Fund IV Fourth life science venture fund with €150M in committed capital, deepening Columbus's presence in Spanish and European biotech venture capital.
- Columbus Innvierte Life Sciences Fund V Fifth life sciences venture fund targeting €210M (€220M with oversubscription) for investment in innovative biotechnology, healthcare, and AI-applied-to-healthcare companies at growth stages.
- Biocity by Columbus Biotechnology park infrastructure initiative providing dedicated facilities for deeptech and biotech companies, with the first site under development in the Basque Country through an €80M, 35,000 sqm investment.
Quantifiable outcome
- €4 billion exit: Viralgen sold to Bayer in 2020 (largest private international biopharma deal that year)
- +4 more outcomes
Companies that use Columbus Venture Partners
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles2 records
Columbus Venture Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Columbus Venture Partners partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CuatrecasassupportingActed as legal adviser to both co-lead investors (Columbus Venture Partners and Mérieux Equity Partners) on the Ona Therapeutics Series B financing transaction.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Columbus Venture Partners competitors and assessment
Company assessmentDirect peers
- Ysios Capital: Spanish VC firm specializing in biotech and medtech investments, headquartered in San Sebastián. Direct peer given shared Spanish base, life-sciences focus, similar fund size profile, and frequent co-investment alongside Columbus (e.g., Ona Therapeutics Series B).
- Alta Life Sciences: Spanish VC firm focused on life-sciences investments from seed to growth stages. Direct peer with overlapping Spanish biotech deal flow, similar early-to-growth-stage strategy, and participation in the same syndicates (e.g., Ona Therapeutics).
- Asabys Partners: Barcelona-based health-tech and life-sciences investor. Direct peer competing for Spanish/European biotech opportunities, with similar early-stage focus and overlapping portfolio themes in therapeutics and medical technology.
- Invivo Ventures: Spanish life-sciences VC firm investing in early-stage therapeutics and medtech. Direct peer with similar Spanish base, co-invested with Columbus in ARTHEx Biotech's Series B, and competes for the same biotech deal flow in Iberia.
- Panakès Partners: Italian venture capital firm focused on early-stage life-sciences investments. Direct peer on cross-border European biotech deals (e.g., co-led deepull's €50M Series C with Columbus) and competes in the same Southern European biotech VC niche.
- Mérieux Equity Partners: Life-sciences investment firm affiliated with the Mérieux family, focused on strategic healthcare and biotech investments. Direct peer, having co-led multiple rounds with Columbus (Ona Therapeutics $86.6M Series B, deepull €50M Series C) and competing for similar European growth-stage biotech deals.
Broad incumbents
- Sofinnova Partners: Paris-based European life-sciences VC with a broader pan-European mandate and Crossover/Industrial Biotech strategies. Larger, broader incumbent competing for the same European biotech deal flow and LP allocations, but with global LPs and larger average check sizes than Columbus.
- Forbion: Pan-European life-sciences VC operating across multiple funds and stages. Broader incumbent competing for European biotech deal flow and LP commitments; offers greater geographic scale but less of an origination/infrastructure-building edge than Columbus.
- EQT Life Sciences: Pan-European life-sciences VC arm of EQT, the global investment firm. Broader incumbent with significantly larger AUM and a wider institutional LP base, operating as a competitor for both deal flow and limited-partner wallet share.
- Jeito Capital: French life-sciences investment firm focused on European biotech and medtech. Broader incumbent operating similar life-sciences VC strategies across European geographies, often partnering with or competing against Columbus for lead-investor roles in mid-to-late-stage biotech rounds.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Columbus Venture Partners social profiles
Digital presenceColumbus Venture Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Columbus Venture Partners leadership team
Management profileNumber of profiles
Profiles14 records
Columbus Venture Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Columbus Venture Partners M&A and investment
M&A and investmentM&A
Investments26 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Columbus Venture Partners
What does Columbus Venture Partners do?
Columbus Venture Partners is an independent venture capital fund manager that invests in early- and growth-stage therapeutic and industrial biotechnology companies, primarily in Spain and Europe, through a series of dedicated life science funds. Across five funds (I–V) totaling €400M+ in committed capital, the firm originates companies internally, builds biotech infrastructure, and delivers exits such as Viralgen (acquired by Bayer for €4B) and Sanifit (acquired by Vifor Pharma for €205M+). The firm also develops the Biocity by Columbus biotech park and operates Fundación Columbus for rare pediatric gene therapies.
Is Columbus Venture Partners a public or private company?
Columbus Venture Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Columbus Venture Partners founded?
Columbus Venture Partners was founded in 2016. It employs 11 to 50 people.
Where is Columbus Venture Partners based?
Columbus Venture Partners is headquartered in Madrid, Spain, in the Europe region.
How does Columbus Venture Partners make money?
Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest.
Who are Columbus Venture Partners's main competitors?
Direct peers on record are Ysios Capital, Alta Life Sciences, Asabys Partners, Invivo Ventures, Panakès Partners and Mérieux Equity Partners. Broad incumbents are Sofinnova Partners, Forbion, EQT Life Sciences and Jeito Capital.
Does Columbus Venture Partners have an API?
No public API is recorded for Columbus Venture Partners.
What industry is Columbus Venture Partners in?
Columbus Venture Partners's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 523940 and its SIC code is 6282.